PTCT
Income statement / Annual
Last year (2025), PTC Therapeutics Inc's total revenue was $1.73 B,
an increase of 114.51% from the previous year.
In 2025, PTC Therapeutics Inc's net income was $682.64 M.
See PTC Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$1.73 B |
$806.78 M |
$937.82 M |
$698.80 M |
$538.59 M |
$380.77 M |
$306.98 M |
$264.73 M |
$194.39 M |
$82.71 M |
| Cost of Revenue |
$0.00
|
$57.40 M
|
$65.49 M
|
$44.68 M
|
$32.33 M
|
$18.94 M
|
$12.14 M
|
$12.67 M
|
$4.58 M
|
$117.63 M
|
| Gross Profit |
$0.00
|
$749.38 M
|
$872.34 M
|
$654.12 M
|
$506.27 M
|
$361.82 M
|
$294.85 M
|
$252.06 M
|
$189.82 M
|
-$34.93 M
|
| Gross Profit Ratio |
0
|
0.93
|
0.93
|
0.94
|
0.94
|
0.95
|
0.96
|
0.95
|
0.98
|
-0.42
|
| Research and Development Expenses |
$455.25 M
|
$534.48 M
|
$666.56 M
|
$651.50 M
|
$540.68 M
|
$477.64 M
|
$257.45 M
|
$171.98 M
|
$117.46 M
|
$117.63 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$347.14 M
|
$300.91 M
|
$332.54 M
|
$326.00 M
|
$285.77 M
|
$245.16 M
|
$202.54 M
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
| Other Expenses |
$61.33 M
|
$216.56 M
|
$312.74 M
|
$124.04 M
|
$54.25 M
|
$70.79 M
|
$76.01 M
|
$129.00 K
|
-$1.28 M
|
-$1.21 M
|
| Operating Expenses |
$863.72 M
|
$1.05 B
|
$1.31 B
|
$1.10 B
|
$880.71 M
|
$793.59 M
|
$536.00 M
|
$348.41 M
|
$254.11 M
|
$214.76 M
|
| Cost And Expenses |
$0.00
|
$1.11 B
|
$1.38 B
|
$1.15 B
|
$913.04 M
|
$812.53 M
|
$548.14 M
|
$361.08 M
|
$258.68 M
|
$214.76 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$152.23 M
|
$166.99 M
|
$129.18 M
|
$90.87 M
|
$86.02 M
|
$56.35 M
|
$12.49 M
|
$12.55 M
|
$12.09 M
|
$8.28 M
|
| Depreciation & Amortization |
$0.00
|
$75.66 M
|
$236.59 M
|
$128.84 M
|
$64.13 M
|
$43.49 M
|
$32.18 M
|
$26.09 M
|
$17.68 M
|
$3.29 M
|
| EBITDA |
$866.94 M |
-$120.46 M |
-$330.34 M |
-$367.78 M |
-$368.18 M |
-$303.09 M |
-$195.26 M |
-$89.47 M |
-$46.61 M |
-$128.77 M |
| EBITDA Ratio |
0.5
|
-0.15
|
-0.35
|
-0.53
|
-0.68
|
-0.8
|
-0.64
|
-0.34
|
-0.24
|
-1.56
|
| Operating Income Ratio |
0.5
|
-0.38
|
-0.47
|
-0.64
|
-0.7
|
-1.13
|
-0.79
|
-0.44
|
-0.33
|
-1.6
|
| Total Other Income/Expenses Net |
-$170.32 M
|
-$60.55 M
|
-$256.61 M
|
-$140.08 M
|
-$143.90 M
|
$28.84 M
|
$1.23 M
|
-$12.43 M
|
-$13.37 M
|
-$9.48 M
|
| Income Before Tax |
$696.62 M
|
-$363.12 M
|
-$696.11 M
|
-$587.49 M
|
-$518.34 M
|
-$402.93 M
|
-$239.93 M
|
-$128.11 M
|
-$77.67 M
|
-$141.54 M
|
| Income Before Tax Ratio |
0.4
|
-0.45
|
-0.74
|
-0.84
|
-0.96
|
-1.06
|
-0.78
|
-0.48
|
-0.4
|
-1.71
|
| Income Tax Expense |
-$13.98 M
|
$176.00 K
|
-$69.51 M
|
-$28.47 M
|
$5.56 M
|
$35.23 M
|
$11.65 M
|
-$29.00 K
|
$1.34 M
|
$569.00 K
|
| Net Income |
$682.64 M
|
-$363.30 M
|
-$626.60 M
|
-$559.02 M
|
-$523.90 M
|
-$438.16 M
|
-$251.58 M
|
-$128.08 M
|
-$79.00 M
|
-$142.11 M
|
| Net Income Ratio |
0.39
|
-0.45
|
-0.67
|
-0.8
|
-0.97
|
-1.15
|
-0.82
|
-0.48
|
-0.41
|
-1.72
|
| EPS |
8.58 |
-4.73 |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
| EPS Diluted |
7.78 |
-4.73 |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
| Weighted Average Shares Out |
$79.53 M
|
$76.85 M
|
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.11 M
|
$34.04 M
|
| Weighted Average Shares Out Diluted |
$88.31 M
|
$76.85 M
|
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.18 M
|
$34.04 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
